Davis Capital Management’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
Davis Capital Management's TGTX Position: Q3 2026 in Review
Davis Capital Management held its TG Therapeutics (TGTX) position steady in Q3 2026 at 8 shares worth $446. The position accounts for ﹤0.01% of the portfolio, ranked #654.
Davis Capital Management first reported a position in TGTX in Q2 2026 and has held it in 2 quarters since. 449 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- Davis Capital Management held 8 shares of TG Therapeutics worth $446 as of Q3 2026.
- Davis Capital Management left its TG Therapeutics share count unchanged in Q3 2026.
- TG Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #654 holding.
- Davis Capital Management first reported a position in TG Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 449 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.